Medivir AB (MVIRb.F) Has Initiated a Phase I Clinical Trial With Its Cathepsin K inhibitor MIV-711

5/29/2012 11:28:35 AM

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Medivir AB (OMX:MVIR), a research-based pharmaceutical company focused on infectious diseases, announced today that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Medivir AB

• Clinical - Phase I

• Clinical - Phase I (World)